Capricor Therapeutics
CAPR
31 hedge funds and large institutions have $16.8M invested in Capricor Therapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 4 closing their positions.
89% more capital invested
Capital invested by funds: $8.87M → $16.8M (+$7.88M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
20% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $1.9M
7% more funds holding
Funds holding: 29 → 31 (+2)
1.01% more ownership
Funds ownership: 10.46% → 11.47% (+1%)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$708K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$269K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$192K |
| 4 |
Millennium Management
New York
|
+$140K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$124K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$102K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$54.3K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$52K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$40.1K |
CAPR Hedge Fund Activity: Q3 2022 in Review
31 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2022, worth a combined $16.8M — up 89% from $8.87M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CAPR positions and 4 closed out — a net gain of 2 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $708K. The largest seller was Susquehanna International Group, cutting an estimated $124K.
- 31 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2022, up from 29 in Q2 2022.
- Funds reported $16.8M of Capricor Therapeutics stock for Q3 2022, up 89% quarter-over-quarter.
- 6 funds opened new Capricor Therapeutics positions in Q3 2022 and 4 closed out, a net change of +2 holders.
- The largest Capricor Therapeutics buyer in Q3 2022 was BlackRock, an estimated $708K added.
- The largest Capricor Therapeutics seller in Q3 2022 was Susquehanna International Group, an estimated $124K sold.
Based on aggregated 13F filings for Q3 2022.